Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection


Introduction and Objectives

The Refractory Urge Incontinence and Botulinum A Toxin Injection (RUBI) randomized clinical trial was designed to compare the effect of 200 U of intra-detrusor Botulinum A toxin (BoNT-A) versus placebo on improvement in urge incontinence symptoms in neurologically normal women with DOI refractory to at least two first-line treatments.

This study also sought to assesses changes in patient quality of life and incidence of urinary incontinence episodes based on standardized bladder diaries. Rates of post-treatment urinary retention and other associated complications are also assessed.


This IRB approved, multi-center registered trial randomized women with refractory urge incontinence, detrusor overactivity incontinence (DOI) and >6 urge incontinence episodes in 3 days to BoNT-A or placebo (2:1). Refractory was defined as inadequate symptom control after > 2 attempts at pharmacotherapy and > 1 other first-line therapies for DOI. The primary outcome measurement was time to failure evidenced by a Patient Global Impression of Improvement (PGI-I) score ≥4 at least two months after the injection or changes in treatment (initiation or increase) at any time after the injection. Safety data, including urinary retention (defined as a PVR >200 ml, irrespective of symptoms), was obtained at specified time points.


Approximately 60% of women who received BoNT-A had a clinical response based on the PGI-I; the median duration of their responses was 373 days, significantly longer than placebo (<62 days, p<0.0001). In the BoNT-A group, urinary retention (12/28, 43%) and urinary tract infection in those with retention (9/12, 75%) exceeded expected ranges and further injections were stopped after 43 subjects had been randomized (28 BoNT-A:15 placebo).


Local injection of 200 U BoNT-A was an effective and durable treatment for refractory OAB. However, transient urinary retention was experienced in 43% of patients. BoNT-A for idiopathic OAB is still under investigation.


Botulinum toxin, Urinary Incontinence, Urinary Retention, Urge Incontinence, Clinical Trial


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.